Production of bacteriocin-like inhibitory substance (BLIS) by Staphylococcus spp. isolates from dogs
Brazilian Journal of Microbiology · 2024
DOI: 10.1007/s42770-024-01532-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brazilian Journal of Microbiology, 2024. Verfasst von Ilana Nascimento de Sousa Santos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes - UFRJ, Av. Carlos Chagas Filho, 373 CCS - Bloco I - Cidade Universitár…. Hauptthemen laut MEDLINE: Staphylococcus, Bacteriocins, Anti-Bacterial Agents, Staphylococcal Infections. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
In the present study, 39 canine isolates of Staphylococcus spp. were tested for antimicrobial substance (AMS) production. Seven AMS producers were identified, whose products exhibited a non-acidic character and a proteinaceous nature, therefore being considered bacteriocin-like inhibitory substances (BLIS). The producer strains of BLIS P1, P16 and I3 showed a broad spectrum of antimicrobial activity. Human, veterinary and plant pathogens, such as Listeria monocytogenes, Klebsiella pneumoniae, Staphylococcus spp. and Clavibacter michiganensis, were among the inhibited micro-organisms, suggesting the potential biotechnological application of these peptides. MALDI-TOF mass spectrometry and 16 S rDNA sequencing identified the producer strains of BLIS P1, P16 and I3 as Staphylococcus pseudintermedius P1, Staphylococcus schleiferi P16 and Staphylococcus pseudintermedius I3. The plasmid profile of these strains suggests that the BLIS production is linked to biosynthetic genes located on plasmids. PCR analyses revealed that BLIS P1, P16 and I3 are different from 11 staphylococcins already described in the literature and that their genomic DNAs do not carry the most prevalent staphylococcal enterotoxin genes. The highest levels of BLIS production were achieved after 18-24 h of growth of the producer strains in TSB medium. Moreover, BLIS P1 and I3 exhibited high resistance to temperature and pH variations, and BLIS P16 maintained 100% of its activity in almost all conditions tested. The characteristics associated with BLIS P1, P16 and I3 described in this work encourage further investigation of these substances, in addition to this study being the first report of BLIS production by a strain of S. schleiferi.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes - UFRJ, Av. Carlos Chagas Filho, 373 CCS - Bloco I - Cidade Universitária, Rio de Janeiro, RJ, 21941-902, Brazil.
- Departamento de Microbiologia e Parasitologia 2, Universidade Federal Fluminense, Niterói, RJ, Brazil.
- Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes - UFRJ, Av. Carlos Chagas Filho, 373 CCS - Bloco I - Cidade Universitária, Rio de Janeiro, RJ, 21941-902, Brazil. mcbastos@micro.ufrj.br.
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Santos, I. N. S., Lilenbaum, W., Moreno, D. S. A., & Bastos, M. D. C. F. (2024). Production of bacteriocin-like inhibitory substance (BLIS) by Staphylococcus spp. isolates from dogs. Brazilian Journal of Microbiology. https://doi.org/10.1007/s42770-024-01532-6
Vancouver
Santos INS, Lilenbaum W, Moreno DSA, Bastos MDCF. Production of bacteriocin-like inhibitory substance (BLIS) by Staphylococcus spp. isolates from dogs. Brazilian Journal of Microbiology. 2024. doi:10.1007/s42770-024-01532-6
BibTeX
@article{Santos2024,
author = {Santos, Ilana Nascimento de Sousa and Lilenbaum, Walter and Moreno, Daniela Sales Alviano and Bastos, Maria do Carmo de Freire},
title = {Production of bacteriocin-like inhibitory substance (BLIS) by Staphylococcus spp. isolates from dogs},
journal = {Brazilian Journal of Microbiology},
year = {2024},
doi = {10.1007/s42770-024-01532-6}
}
EUVIMED